Comparison of the effect of injection of platelet-rich plasma and growth hormone into the knee joint and their effect on knee pain

Comparison of intra-articular injection of platelet rich plasma (PRP) versus combined PRP/somatropin on pain and joint range of motion in patients with knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015070210599N4

Enrollment

Registered

2016-01-17

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis. Polyarthrosis, unspecified

Interventions

Intervention 1: Intervention 1. Platelet-rich plasma, 8 ml, intra-articular injection. Intervention 2: Intervention 2. Platelet-rich plasma in combination with 4 units of growth hormone, made in Biosi

Treatment - Drugs

Intervention 1. Platelet-rich plasma, 8 ml, intra-articular injection

Intervention 2. Platelet-rich plasma in combination with 4 units of growth hormone, made in Biosidus company, Argentina, 8 ml, intra-articular injection

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 30-70 years; Knee osteoarthritis stage I-III according to American Rheumatologist society criteria or radiologic criteria I-III according to Kalgreen-Lawrence criteria. Exclusion criteria: Addiction to opioids or alcohol; history of rheumatoid arthritis or any rheumatologic disease; hemophilia.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Once a month to three times. Method of measurement: WOMAC score.	—

Secondary

Measure	Time frame
Joint movement. Timepoint: Once a month to three times. Method of measurement: WOMAC score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Damoon Azad

Iran University of Medical Sciences

damonazad@yahoo.com+98 21 8670 2503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026